| Overview |
| bs-23550R-Cy5.5 |
| NCR1 Polyclonal Antibody, Cy5.5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NCR1 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| O76036 |
| 9437 |
| Cell membrane |
| Natural killer cell p46-related protein; Natural cytotoxicity triggering receptor 1; NK-p46; NKp46; NK cell-activating receptor; Lymphocyte antigen 94 homolog; CD335; CD 335; LY94; NCTR1_HUMAN. |
| The natural cytotoxicity receptors (NCRs) are a recently characterized family of Ig-like activation receptors that appear to be major triggering receptors in tumor cell recognition. NCR1 is a glycoprotein that has two extracellular Ig-like domains followed by a ~40 amino acid residue stalk region, a type I transmembrane domain, and a short cytoplasmic tail. NCR1 has been shown to represent a novel NK cell-specific molecule involved in human NK cell activation. NCR1 has been implicated in NK cell-mediated lysis of several autologous tumor cells and pathogen-infected cell lines. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz